[Acute coronary syndromes without ST segment elevation]
Marc Genest1, Gilbert Pochmalicki
1Service de cardiologie CHG Provins, Provins. marc.genest@wanadoo.fr
Insights
New classifications for acute coronary syndromes (ACS) guide rapid intervention. Treatment involves aspirin, clopidogrel, enoxaparin, and risk-stratified therapies like antiplatelet agents and coronary revascularization for high-risk patients.
Area of Science:
- Cardiology
- Emergency Medicine
Background:
- Acute coronary syndromes (ACS) necessitate timely therapeutic strategies.
- Traditional diagnostic markers like Q-wave or MB creatinine kinase are insufficient for early classification.
- Electrocardiogram (ECG) findings are crucial for distinguishing ST-segment elevation ACS from non-ST-segment elevation ACS.
Purpose of the Study:
- To outline current therapeutic approaches for acute coronary syndromes.
- To emphasize the importance of early risk stratification and intervention.
Main Methods:
- Review of current treatment guidelines for ACS.
- Classification based on electrocardiogram findings (ST-segment elevation vs. non-ST-segment elevation).
- Pharmacological management including antiplatelet drugs, anticoagulants, beta-blockers, and other supportive treatments.
Main Results:
- Aspirin and clopidogrel are standard antiplatelet therapies.
- Enoxaparin shows superiority over unfractionated heparin as an anticoagulant.
- High-risk patients benefit from early coronary revascularization (within 24 hours).
Conclusions:
- Modern ACS management relies on early ECG-based classification and risk stratification.
- Pharmacological interventions are tailored to specific ACS types and patient risk.
- Timely coronary revascularization is recommended for high-risk individuals.
Abstract:
NEW DENOMINATIONS: With the arrival of new therapeutic strategies requiring rapid intervention, acute coronary syndromes required classification on earlier data than the Q-wave or MB creatinine kinase. In a patient with anginal pain and depending on the electrocardiogram, we now distinguish syndromes with or without ST segment elevation. REGARDING ANTIPLATELET DRUGS: Aspirin is used in all cases, as well as clopidogrel. Anti PG IIb-IIIa agents are set aside only for the forms at risk, when an angioplasty is envisaged in the short term. ANTICOAGULANTS: Enoxaparin has demonstrated its superiority over unfractionated heparin. In general, the biological controls are not indispensables; they can however be used in certain cases (notably elderly patients). OTHER TREATMENTS: These are beta-blockers (first dose via the intravenous route in the case of persisting pain, then relay to the oral route), calcium-channel blockers (diltiazem, verapamil) when beta-blockers are contraindicated, nitrate derivatives with demonstrated antalgic effect but not to be used if an extension to the right ventricle or low blood pressure is suspected, nasal oxygen in the case of cyanosis or respiratory distress, enzyme conversion inhibitors if hypertension persists, and repeated intravenous injections of morphine in the case of persisting intense pain. CORONARY REVASCULARISATION: In all the patients considered at high risk, coronary revascularisation is recommended within the first 24 hours, when technically possible.
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Angina II: Classification
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome V: Nursing Management


